|Budget Amount *help
¥2,100,000 (Direct Cost : ¥2,100,000)
Fiscal Year 1993 : ¥800,000 (Direct Cost : ¥800,000)
Fiscal Year 1992 : ¥600,000 (Direct Cost : ¥600,000)
Fiscal Year 1991 : ¥700,000 (Direct Cost : ¥700,000)
A novel squamous cell cancer associated antibody (SCCAAb) was developed, since detection of SCC associated antigens (SCCAA) against the cells and tissues of SCC of head and neck is highly effective for early diagnosis.
SCCAAb was prepared by immunization to rabbit with specific components from pharyngeal SCC cell Line.
Western blot analysis revealed that SCCAA consist of four components from 120KD to 225KD.
Immunological technique by ABC was applied and SCCAAb, commercial anti-bodies ( Involcrin, Keratin, EGF-R, EMA, PKK2, K-ras (P21) ) were used as first antibodies.
Following results were obtained.
Positive number and percent were 34/40 (85%) with SCCAAb, 28/34 (82%) with Involcrine, 29/30 (97%) with Kratin, 26/39 (67%) with EGF-R, 25/37 (68%) with EMA, 26/37 (70%) with PKK2, and 15/37 (1%) with K-ras (P21). False positive number and percent in benign specimens, 11% with SCCAAb, 42% with Involcrine, 85% with Kratin, 34% with EGF-R 28% with EMA, 49% with PKK2 and 18% with K-ras (P21), respectively.